Revenue
No reported data
Palomino Laboratories Inc. (PALX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating expenses | $2.7M | $6,123 | — |
| Operating income | −$2.7M | −$6,123 | −$83,937 |
| Net income | −$3.2M | −$16,198 | −$83,937 |
| Basic EPSper diluted share | -$0.47 | -$0.01 | -$0.02 |
| Diluted EPSper diluted share | -$0.47 | -$0.01 | -$0.02 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 20, 2026Form 4 | Ogawa RichardSecretary | BuyCommon Stock | 12.5K | $4.00 | $50.0K | 1.76M |
| Apr 20, 2026Form 4 | Denbaars StevenDirector | BuyCommon Stock | 12.5K | $4.00 | $50.0K | 1.76M |
| Sep 29, 2025Form 4 | Shealy Jeffrey B.President and CEO | SellWarrants · derivative | 833.3K | $1.20 | $1000.0K | 4.67M |
| Sep 29, 2025Form 4 | Denbaars StevenDirector | SellWarrants · derivative | 125.0K | $1.20 | $150.0K | 125.0K |
| Sep 29, 2025Form 4 | Ogawa RichardSecretary | SellWarrants · derivative | 125.0K | $1.20 | $150.0K | 125.0K |